Skip to content
Screener

Pre-Tax Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.09B+130%
Eli Lilly logo
Eli LillyLLY
$8.85B+156%
Pfizer logo
PfizerPFE
-$653M-121%
Merck & Co. logo
Merck & Co.MRK
-$3.53B-160%
Amgen logo
AmgenAMGN
$2.77B+76.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$128M-14.3%

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$38.79B+460%
Enterprise value$38.5B+479%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-208969
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Change in fair value of warrant liability(15,788)2,439
Other expense, net(117)(10)
Total non-operating income (expense), net(8,594)27,344
Loss before income taxes(453,816)(213,416)
Net loss$(453,816)$(213,416)
Net loss per share attributable to common stockholders, basic and diluted$(2.29)$(1.13)
Weighted-average common shares used to compute net loss per share, basic and diluted198,098,047188,145,904
Comprehensive loss:

Item 1. Financial Statements.

FAQ

What is Revolution Medicines, Inc.'s pre-tax income?
Revolution Medicines, Inc. (RVMD) reported pre-tax income of -$453.82M in Q1 2026.
How has Revolution Medicines, Inc.'s pre-tax income changed year-over-year?
Revolution Medicines, Inc.'s pre-tax income decreased by 112.6% year-over-year, from -$213.42M to -$453.82M.
What is the long-term trend for Revolution Medicines, Inc.'s pre-tax income?
Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s pre-tax income has grown at a 56.8% compound annual growth rate (CAGR), from -$187.09M to -$1.13B.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Revolution Medicines, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude